We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PAYX:NASDAQPaychex, Inc. Analysis

Data as of 2026-05-19 - not real-time

$96.52

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Revenue growth accelerated in the latest quarter, beating analyst forecasts. The company posted a non‑GAAP profit per share that exceeded consensus estimates. Dividend yield remains among the highest in the technology‑software sector, providing appealing income. However, the payout ratio sits near the upper limit of sustainability, raising concerns about cash coverage. Valuation metrics show the market price trading well above the discounted cash‑flow estimate, suggesting an overvalued stance. The price‑to‑earnings multiple, while lower than the industry average, does not offset the premium implied by the market.
Technical analysis reveals a bullish MACD crossover and an RSI in the modestly positive zone. The stock is hovering near a key resistance level, with the 20‑day and 50‑day moving averages converging just below the current price. Volume has been on an upward trend, supporting the recent price action. The beta is exceptionally low, indicating limited sensitivity to broader market moves. Volatility over the past month remains elevated, reflecting price swings despite the low beta. Considering the strong dividend, growth momentum, but valuation premium and cash‑flow constraints, a cautious stance is warranted.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with limited upside
  • Bullish MACD but valuation premium
  • High dividend yield but sustainability concerns

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Continued revenue growth and earnings beat
  • Dividend income offset by valuation risk
  • Low beta providing defensive characteristics

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Stable market position in payroll and HCM services
  • Demographic tailwinds for small‑to‑mid‑size business adoption
  • Potential for valuation re‑rating as cash flow improves

Key Metrics & Analysis

Financial Health

Revenue Growth19.90%
Profit Margin26.63%
P/E Ratio21.3
Debt/Equity124.91
P/B Ratio8.6
Op. Cash Flow$1.2B
Industry P/E37.5

Technical Analysis

TrendNeutral
RSI60.1
Support$87.43
Resistance$96.74
MA 20$92.43
MA 50$91.98
MA 200$110.96
MACDBullish
VolumeIncreasing
Fear & Greed Index89.66

Valuation

Fair Value$58.40
Target Price$100.93
Upside/Downside4.57%
GradeOvervalued
TypeBlend
Dividend Yield5.04%

Risk Assessment

Beta0.29
Volatility32.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.